2.155
Inovio Pharmaceuticals Inc Aktie (INO) Neueste Nachrichten
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio’s SWOT analysis: dna immunotherapy firm faces crucial year for stock - Investing.com Australia
Inovio shareholders approve board nominees and proposals By Investing.com - Investing.com Canada
Inovio shareholders approve board nominees and proposals - Investing.com Australia
Inovio Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
INOVIO Reports Q1 2025 Results and Key Developments in DNA Medicines - MyChesCo
Q2 EPS Estimate for Inovio Pharmaceuticals Cut by Analyst - Defense World
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Inovio Pharmaceuticals’ Earnings Call: Progress Amid Challenges - TipRanks
Inovio Pharmaceuticals (INO) Sees Price Target Adjustment by Opp - GuruFocus
Inovio outlines BLA submission timeline for INO-3107 and reports $68.4M cash position while advancing DNA medicine pipeline - MSN
Inovio Pharmaceuticals (INO) Maintains Sector Perform Rating by RBC Capital | INO Stock News - GuruFocus
Oppenheimer cuts Inovio stock price target to $13 By Investing.com - Investing.com Nigeria
INO Reports Strong Q1 Revenue, Progress on INO-3107 Submission | - GuruFocus
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2025 Earnings Call Transcript - Insider Monkey
Inovio (INO) Receives Revised Price Target from Oppenheimer | IN - GuruFocus
Inovio Pharmaceuticals: Hold Rating Due to Financial Losses and Uncertain Development Timeline - TipRanks
Inovio stock holds $12 target, JMP affirms Market Outperform By Investing.com - Investing.com Canada
Inovio stock holds $12 target, JMP affirms Market Outperform - Investing.com Australia
Inovio Pharmaceuticals Inc (INO) Q1 2025 Earnings Call Highlights: Strategic Cost Management ... - Yahoo Finance
Inovio Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Inovio Pharmaceuticals (INO) Advances BLA Submission for INO-310 - GuruFocus
INOVIO Reports First Quarter 2025 Financial Results and Recent B - GuruFocus
Earnings call transcript: Inovio’s Q1 2025 sees narrowed losses, stock rises - Investing.com India
Inovio: Q1 Earnings Snapshot - San Francisco Chronicle
Inovio Pharmaceuticals Inc (INO) Q1 2025 Earnings: EPS of -$0.51 - GuruFocus
Inovio Pharmaceuticals Q1 Operating Expenses USD 25.1 Million - marketscreener.com
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire
Inovio Pharmaceuticals Q1 25 Earnings Conference Call At 4:30 PM ET - Nasdaq
Options Volatility and Implied Earnings Moves Today, May 13, 2025 - The Globe and Mail
Inovio Pharmaceuticals (NASDAQ:INO) Lowered to “Sell” Rating by StockNews.com - Defense World
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | INO Stock News - GuruFocus
Inovio Pharmaceuticals (INO) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Inovio at The Citizens JMP Life Sciences Conference: DNA Platform Progress - Investing.com Australia
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares Sold by Renaissance Technologies LLC - Defense World
Inovio Pharmaceuticals (NASDAQ:INO) Cut to Sell at StockNews.com - Defense World
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025 - Kilgore News Herald
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INOVIO to Announce Q1 2025 Results and Host Live Webcast on May 13 - MyChesCo
Geode Capital Management LLC Boosts Stake in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
INOVIO to Present at Upcoming Scientific and Investor Conferences - The Bradford Era
INOVIO to Present at Upcoming Scientific and Investor Conferences | INO Stock News - GuruFocus
XTX Topco Ltd Acquires New Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):